In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study
Author(s) -
Andrew Walkty,
James A. Karlowsky,
Melanie Baxter,
Heather J. Adam,
George G. Zhanel
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02068-18
Subject(s) - microbiology and biotechnology , morganella morganii , broth microdilution , proteus mirabilis , proteus , gram , providencia , aminoglycoside , antimicrobial , staphylococcus aureus , medicine , enterobacteriaceae , biology , antibiotics , escherichia coli , minimum inhibitory concentration , bacteria , biochemistry , genetics , gene
The Clinical and Laboratory Standards Institute (CLSI) broth microdilution method was used to evaluate thein vitro activities of plazomicin and comparator antimicrobial agents against 7,712 Gram-negative and 4,481 Gram-positive bacterial pathogens obtained from 2013 to 2017 from patients in Canadian hospitals as part of the CANWARD Surveillance Study. Plazomicin demonstrated potentin vitro activity againstEnterobacteriaceae (MIC90 ≤ 1 µg/ml for all species tested exceptProteus mirabilis andMorganella morganii ), including aminoglycoside-nonsusceptible, extended-spectrum β-lactamase (ESBL)-positive, and multidrug-resistant (MDR) isolates.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom